These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 35939200)
1. Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. Agarwal P; Mohamed A Curr Treat Options Oncol; 2022 Sep; 23(9):1233-1246. PubMed ID: 35939200 [TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329 [TBL] [Abstract][Full Text] [Related]
3. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Dawod M; Gordoa TA; Cives M; De Mestier L; Crona J; Spada F; Oberg K; Pavel M; Lamarca A Curr Treat Options Oncol; 2021 Jun; 22(8):73. PubMed ID: 34185197 [TBL] [Abstract][Full Text] [Related]
4. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Chandrasekharan C Surg Oncol Clin N Am; 2020 Apr; 29(2):293-316. PubMed ID: 32151362 [TBL] [Abstract][Full Text] [Related]
5. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E; BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081 [TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. Prinzi N; Raimondi A; Maccauro M; Milione M; Garanzini E; Torchio M; Corti F; Nichetti F; Lo Russo G; Giacomelli L; Mazzaferro V; Di Bartolomeo M; Seregni E; de Braud F; Pusceddu S Future Oncol; 2019 Sep; 15(26):3015-3024. PubMed ID: 31424273 [No Abstract] [Full Text] [Related]
8. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R; Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153 [TBL] [Abstract][Full Text] [Related]
9. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Cloyd JM; Konda B; Shah MH; Pawlik TM Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383 [TBL] [Abstract][Full Text] [Related]
10. Real-world comparison of healthcare resource utilization and costs of [ Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254 [TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of neuroendocrine tumors with hepatic metastases. Demirkan BH; Eriksson B Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287 [TBL] [Abstract][Full Text] [Related]
12. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646 [TBL] [Abstract][Full Text] [Related]
14. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Cives M; Strosberg J Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Modica R; Liccardi A; Minotta R; Cannavale G; Benevento E; Colao A Expert Rev Endocrinol Metab; 2022 Sep; 17(5):389-403. PubMed ID: 35822906 [TBL] [Abstract][Full Text] [Related]